MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13023-015-0326-6

Медицинская библиотека · Orphanet journal of rare diseases · 2015

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.

Suhr Ole B, Coelho Teresa, Buades Juan, Pouget Jean, Conceicao Isabel, Berk John, Schmidt Hartmut, Waddington-Cruz Márcia, Campistol Josep M, Bettencourt Brian R, Vaishnaw Akshay, Gollob Jared, Adams David

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Transthyretin-mediated amyloidosis is an inherited, progressively debilitating disease caused by mutations in the transthyretin gene. This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of patisiran (ALN-TTR02), a small interfering RNA encapsulated within lipid nanoparticles, in patients with transthyretin-mediated familial amyloid polyneuropathy (FAP).

METHODS

In this phase II study, patients with FAP were administered 2 intravenous infusions of patisiran at one of the following doses: 0.01 (n = 4), 0.05 (n = 3), 0.15 (n = 3), or 0.3 (n = 7) mg/kg every 4 weeks (Q4W), or 0.3 mg/kg (n = 12) every 3 weeks (Q3W).

RESULTS

Of 29 patients in the intent-to-treat population, 26 completed the study. Administration of patisiran led to rapid, dose-dependent, and durable knockdown of transthyretin, with the maximum effect seen with patisiran 0.3 mg/kg; levels of mutant and wild-type transthyretin were reduced to a similar extent in Val30Met patients. A mean level of knockdown exceeding 85 % after the second dose, with maximum knockdown of 96 %, was observed for the Q3W dose. The most common treatment-related adverse event (AE) was mild-to-moderate infusion-related reactions in 10.3 % of patients. Four serious AEs (SAEs) were reported in 1 patient administered 0.3 mg/kg Q3W (urinary tract infection, sepsis, nausea, vomiting), and 1 patient administered 0.3 mg/kg Q4W had 1 SAE (extravasation-related cellulitis).

CONCLUSIONS

Patisiran was generally well tolerated and resulted in significant dose-dependent knockdown of transthyretin protein in patients with FAP. Patisiran 0.3 mg/kg Q3W is currently in phase III development.

TRIAL REGISTRATION NUMBER: NCT01617967 .

Для цитирования: Suhr Ole B, Coelho Teresa, Buades Juan, Pouget Jean, Conceicao Isabel, Berk John, Schmidt Hartmut, Waddington-Cruz Márcia, Campistol Josep M, Bettencourt Brian R, Vaishnaw Akshay, Gollob Jared, Adams David. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.. Orphanet journal of rare diseases. 2015. DOI: 10.1186/s13023-015-0326-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.